Tech Company Financing Transactions
Dantari Funding Round
On 12/8/2022, Dantari raised $47 million in Series A funding from Westlake Village BioPartners, Alexandria Venture Investments and Caltech.
Transaction Overview
Company Name
Announced On
12/8/2022
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for the advancement of its differentiated antibody-drug conjugate (ADC) and chemotherapeutic platforms.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1290 Rancho Conejo Blvd 103
Thousand Oaks, CA 91320
USA
Thousand Oaks, CA 91320
USA
Phone
Undisclosed
Website
Email Address
Overview
Dantari is a clinical stage biotechnology company committed to creating breakthrough therapies for the treatment of cancer and other serious diseases. We are excited by our rapid development and the capability of our proprietary platform technology to improve the health of patients through.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Markus
Browse more venture capital transactions:
Prev: 12/8/2022: UnaBiz venture capital transaction
Next: 12/8/2022: Earn Alliance venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs